nodes	percent_of_prediction	percent_of_DWPC	metapath
Diclofenac—ALB—acquired immunodeficiency syndrome	0.141	1	CbGaD
Diclofenac—UGT1A1—Abacavir—acquired immunodeficiency syndrome	0.0402	0.0695	CbGbCtD
Diclofenac—UGT2B7—Zidovudine—acquired immunodeficiency syndrome	0.0218	0.0376	CbGbCtD
Diclofenac—ABCC1—Amprenavir—acquired immunodeficiency syndrome	0.0213	0.0368	CbGbCtD
Diclofenac—SLC22A6—Stavudine—acquired immunodeficiency syndrome	0.0211	0.0364	CbGbCtD
Diclofenac—SLC22A11—Zidovudine—acquired immunodeficiency syndrome	0.0207	0.0357	CbGbCtD
Diclofenac—ABCC4—Zidovudine—acquired immunodeficiency syndrome	0.0193	0.0333	CbGbCtD
Diclofenac—ABCC1—Indinavir—acquired immunodeficiency syndrome	0.0184	0.0318	CbGbCtD
Diclofenac—ABCC1—Ritonavir—acquired immunodeficiency syndrome	0.0161	0.0279	CbGbCtD
Diclofenac—ABCC1—Saquinavir—acquired immunodeficiency syndrome	0.0161	0.0279	CbGbCtD
Diclofenac—SLC22A6—Didanosine—acquired immunodeficiency syndrome	0.016	0.0276	CbGbCtD
Diclofenac—ABCC4—Lamivudine—acquired immunodeficiency syndrome	0.0149	0.0257	CbGbCtD
Diclofenac—SLC22A8—Zidovudine—acquired immunodeficiency syndrome	0.012	0.0208	CbGbCtD
Diclofenac—ABCC1—Lamivudine—acquired immunodeficiency syndrome	0.012	0.0207	CbGbCtD
Diclofenac—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0118	0.0204	CbGbCtD
Diclofenac—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0111	0.0191	CbGbCtD
Diclofenac—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0111	0.0191	CbGbCtD
Diclofenac—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.01	0.0173	CbGbCtD
Diclofenac—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.0084	0.0145	CbGbCtD
Diclofenac—SLC22A6—Zidovudine—acquired immunodeficiency syndrome	0.00838	0.0145	CbGbCtD
Diclofenac—CYP2E1—Ritonavir—acquired immunodeficiency syndrome	0.0077	0.0133	CbGbCtD
Diclofenac—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.0076	0.0131	CbGbCtD
Diclofenac—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.00759	0.0131	CbGbCtD
Diclofenac—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.00759	0.0131	CbGbCtD
Diclofenac—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.00749	0.0129	CbGbCtD
Diclofenac—ALB—Saquinavir—acquired immunodeficiency syndrome	0.00745	0.0129	CbGbCtD
Diclofenac—ALB—Zidovudine—acquired immunodeficiency syndrome	0.00714	0.0123	CbGbCtD
Diclofenac—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.00705	0.0122	CbGbCtD
Diclofenac—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.00691	0.0119	CbGbCtD
Diclofenac—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0065	0.0112	CbGbCtD
Diclofenac—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0065	0.0112	CbGbCtD
Diclofenac—SLC22A6—Lamivudine—acquired immunodeficiency syndrome	0.00649	0.0112	CbGbCtD
Diclofenac—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.00637	0.011	CbGbCtD
Diclofenac—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.00637	0.011	CbGbCtD
Diclofenac—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.00623	0.0108	CbGbCtD
Diclofenac—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.00588	0.0102	CbGbCtD
Diclofenac—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.00586	0.0101	CbGbCtD
Diclofenac—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.00586	0.0101	CbGbCtD
Diclofenac—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.00576	0.00994	CbGbCtD
Diclofenac—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.00576	0.00994	CbGbCtD
Diclofenac—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00568	0.00982	CbGbCtD
Diclofenac—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.00552	0.00953	CbGbCtD
Diclofenac—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0055	0.0095	CbGbCtD
Diclofenac—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.00534	0.00922	CbGbCtD
Diclofenac—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0053	0.00915	CbGbCtD
Diclofenac—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0053	0.00915	CbGbCtD
Diclofenac—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00514	0.00888	CbGbCtD
Diclofenac—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.00493	0.00851	CbGbCtD
Diclofenac—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.00483	0.00834	CbGbCtD
Diclofenac—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.00483	0.00834	CbGbCtD
Diclofenac—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.00463	0.00799	CbGbCtD
Diclofenac—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00457	0.0079	CbGbCtD
Diclofenac—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00446	0.00769	CbGbCtD
Diclofenac—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00444	0.00767	CbGbCtD
Diclofenac—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00444	0.00766	CbGbCtD
Diclofenac—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00431	0.00744	CbGbCtD
Diclofenac—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00401	0.00693	CbGbCtD
Diclofenac—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00401	0.00693	CbGbCtD
Diclofenac—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0039	0.00673	CbGbCtD
Diclofenac—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0039	0.00673	CbGbCtD
Diclofenac—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00385	0.00665	CbGbCtD
Diclofenac—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00374	0.00645	CbGbCtD
Diclofenac—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00362	0.00626	CbGbCtD
Diclofenac—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00341	0.00588	CbGbCtD
Diclofenac—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00341	0.00588	CbGbCtD
Diclofenac—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00308	0.00532	CbGbCtD
Diclofenac—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00308	0.00532	CbGbCtD
Diclofenac—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00289	0.00499	CbGbCtD
Diclofenac—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00266	0.00459	CbGbCtD
Diclofenac—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00258	0.00446	CbGbCtD
Diclofenac—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00233	0.00403	CbGbCtD
Diclofenac—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00233	0.00403	CbGbCtD
Diclofenac—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00224	0.00386	CbGbCtD
Diclofenac—CXCR1—blood—acquired immunodeficiency syndrome	0.00152	0.0276	CbGeAlD
Diclofenac—PLA2G2A—blood plasma—acquired immunodeficiency syndrome	0.00149	0.027	CbGeAlD
Diclofenac—CXCR1—bone marrow—acquired immunodeficiency syndrome	0.00148	0.0267	CbGeAlD
Diclofenac—CXCR1—lung—acquired immunodeficiency syndrome	0.00134	0.0242	CbGeAlD
Diclofenac—TTR—blood plasma—acquired immunodeficiency syndrome	0.00113	0.0204	CbGeAlD
Diclofenac—UGT1A1—blood plasma—acquired immunodeficiency syndrome	0.00107	0.0193	CbGeAlD
Diclofenac—CXCR1—lymph node—acquired immunodeficiency syndrome	0.000914	0.0165	CbGeAlD
Diclofenac—ASIC1—spinal cord—acquired immunodeficiency syndrome	0.000873	0.0158	CbGeAlD
Diclofenac—ASIC1—nervous system—acquired immunodeficiency syndrome	0.000736	0.0133	CbGeAlD
Diclofenac—ASIC1—central nervous system—acquired immunodeficiency syndrome	0.000709	0.0128	CbGeAlD
Diclofenac—ABCC4—blood plasma—acquired immunodeficiency syndrome	0.000696	0.0126	CbGeAlD
Diclofenac—KCNQ3—lung—acquired immunodeficiency syndrome	0.000632	0.0114	CbGeAlD
Diclofenac—TTR—retina—acquired immunodeficiency syndrome	0.000617	0.0111	CbGeAlD
Diclofenac—KCNQ3—nervous system—acquired immunodeficiency syndrome	0.000585	0.0106	CbGeAlD
Diclofenac—PLA2G2A—lymphoid tissue—acquired immunodeficiency syndrome	0.000581	0.0105	CbGeAlD
Diclofenac—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.000579	0.0105	CbGeAlD
Diclofenac—PLA2G2A—digestive system—acquired immunodeficiency syndrome	0.000574	0.0104	CbGeAlD
Diclofenac—KCNQ3—central nervous system—acquired immunodeficiency syndrome	0.000564	0.0102	CbGeAlD
Diclofenac—ASIC1—brain—acquired immunodeficiency syndrome	0.000563	0.0102	CbGeAlD
Diclofenac—PLA2G2A—blood—acquired immunodeficiency syndrome	0.000546	0.00988	CbGeAlD
Diclofenac—ASIC1—lymph node—acquired immunodeficiency syndrome	0.000544	0.00982	CbGeAlD
Diclofenac—CXCL8—blood—acquired immunodeficiency syndrome	0.000541	0.00978	CbGeAlD
Diclofenac—KCNQ2—nervous system—acquired immunodeficiency syndrome	0.000539	0.00974	CbGeAlD
Diclofenac—CYP2C18—digestive system—acquired immunodeficiency syndrome	0.000524	0.00946	CbGeAlD
Diclofenac—CXCL8—bone marrow—acquired immunodeficiency syndrome	0.000523	0.00946	CbGeAlD
Diclofenac—CXCL8—spinal cord—acquired immunodeficiency syndrome	0.000521	0.00942	CbGeAlD
Diclofenac—KCNQ2—central nervous system—acquired immunodeficiency syndrome	0.000519	0.00937	CbGeAlD
Diclofenac—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.000505	0.00913	CbGeAlD
Diclofenac—CXCL8—vagina—acquired immunodeficiency syndrome	0.000501	0.00906	CbGeAlD
Diclofenac—UGT2B7—digestive system—acquired immunodeficiency syndrome	0.000483	0.00873	CbGeAlD
Diclofenac—PLA2G2A—lung—acquired immunodeficiency syndrome	0.000479	0.00866	CbGeAlD
Diclofenac—CXCL8—lung—acquired immunodeficiency syndrome	0.000474	0.00857	CbGeAlD
Diclofenac—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000473	0.00854	CbGeAlD
Diclofenac—SLC22A11—digestive system—acquired immunodeficiency syndrome	0.00047	0.0085	CbGeAlD
Diclofenac—CYP2C18—vagina—acquired immunodeficiency syndrome	0.000462	0.00836	CbGeAlD
Diclofenac—PTGS1—endothelium—acquired immunodeficiency syndrome	0.000461	0.00834	CbGeAlD
Diclofenac—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.000453	0.00819	CbGeAlD
Diclofenac—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000449	0.00811	CbGeAlD
Diclofenac—KCNQ3—brain—acquired immunodeficiency syndrome	0.000447	0.00809	CbGeAlD
Diclofenac—SLCO1C1—spinal cord—acquired immunodeficiency syndrome	0.000445	0.00804	CbGeAlD
Diclofenac—PLA2G2A—nervous system—acquired immunodeficiency syndrome	0.000444	0.00802	CbGeAlD
Diclofenac—PTGS2—endothelium—acquired immunodeficiency syndrome	0.000441	0.00797	CbGeAlD
Diclofenac—TTR—lymphoid tissue—acquired immunodeficiency syndrome	0.000438	0.00792	CbGeAlD
Diclofenac—TTR—digestive system—acquired immunodeficiency syndrome	0.000433	0.00783	CbGeAlD
Diclofenac—PLA2G2A—central nervous system—acquired immunodeficiency syndrome	0.000427	0.00772	CbGeAlD
Diclofenac—CYP2E1—blood plasma—acquired immunodeficiency syndrome	0.000425	0.00768	CbGeAlD
Diclofenac—TTR—blood—acquired immunodeficiency syndrome	0.000413	0.00746	CbGeAlD
Diclofenac—KCNQ2—brain—acquired immunodeficiency syndrome	0.000412	0.00744	CbGeAlD
Diclofenac—UGT1A1—digestive system—acquired immunodeficiency syndrome	0.000411	0.00742	CbGeAlD
Diclofenac—PTGS1—blood plasma—acquired immunodeficiency syndrome	0.00041	0.0074	CbGeAlD
Diclofenac—TTR—bone marrow—acquired immunodeficiency syndrome	0.000399	0.00721	CbGeAlD
Diclofenac—TTR—spinal cord—acquired immunodeficiency syndrome	0.000397	0.00718	CbGeAlD
Diclofenac—ALOX5—lymphoid tissue—acquired immunodeficiency syndrome	0.000397	0.00718	CbGeAlD
Diclofenac—ALOX5—digestive system—acquired immunodeficiency syndrome	0.000392	0.00709	CbGeAlD
Diclofenac—PTGS2—blood plasma—acquired immunodeficiency syndrome	0.000392	0.00708	CbGeAlD
Diclofenac—UGT1A1—blood—acquired immunodeficiency syndrome	0.000391	0.00707	CbGeAlD
Diclofenac—SLCO1C1—nervous system—acquired immunodeficiency syndrome	0.000375	0.00677	CbGeAlD
Diclofenac—ALOX5—blood—acquired immunodeficiency syndrome	0.000374	0.00676	CbGeAlD
Diclofenac—ALOX5—bone marrow—acquired immunodeficiency syndrome	0.000362	0.00654	CbGeAlD
Diclofenac—TTR—lung—acquired immunodeficiency syndrome	0.000362	0.00654	CbGeAlD
Diclofenac—SLCO1C1—central nervous system—acquired immunodeficiency syndrome	0.000361	0.00652	CbGeAlD
Diclofenac—SCN4A—nervous system—acquired immunodeficiency syndrome	0.000344	0.00622	CbGeAlD
Diclofenac—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000342	0.00618	CbGeAlD
Diclofenac—PLA2G2A—brain—acquired immunodeficiency syndrome	0.000339	0.00613	CbGeAlD
Diclofenac—CXCL8—brain—acquired immunodeficiency syndrome	0.000336	0.00607	CbGeAlD
Diclofenac—TTR—nervous system—acquired immunodeficiency syndrome	0.000335	0.00605	CbGeAlD
Diclofenac—SCN4A—central nervous system—acquired immunodeficiency syndrome	0.000331	0.00599	CbGeAlD
Diclofenac—ALOX5—lung—acquired immunodeficiency syndrome	0.000328	0.00592	CbGeAlD
Diclofenac—PLA2G2A—lymph node—acquired immunodeficiency syndrome	0.000328	0.00592	CbGeAlD
Diclofenac—CXCL8—lymph node—acquired immunodeficiency syndrome	0.000324	0.00586	CbGeAlD
Diclofenac—TTR—central nervous system—acquired immunodeficiency syndrome	0.000322	0.00583	CbGeAlD
Diclofenac—ALOX5—nervous system—acquired immunodeficiency syndrome	0.000303	0.00548	CbGeAlD
Diclofenac—ALOX5—central nervous system—acquired immunodeficiency syndrome	0.000292	0.00528	CbGeAlD
Diclofenac—SLCO1C1—brain—acquired immunodeficiency syndrome	0.000286	0.00518	CbGeAlD
Diclofenac—SLCO1C1—lymph node—acquired immunodeficiency syndrome	0.000277	0.005	CbGeAlD
Diclofenac—ABCC4—digestive system—acquired immunodeficiency syndrome	0.000268	0.00484	CbGeAlD
Diclofenac—SCN4A—brain—acquired immunodeficiency syndrome	0.000263	0.00476	CbGeAlD
Diclofenac—SLC22A6—brain—acquired immunodeficiency syndrome	0.000262	0.00474	CbGeAlD
Diclofenac—TTR—brain—acquired immunodeficiency syndrome	0.000256	0.00463	CbGeAlD
Diclofenac—ABCC4—blood—acquired immunodeficiency syndrome	0.000255	0.00461	CbGeAlD
Diclofenac—SLC22A8—blood—acquired immunodeficiency syndrome	0.000253	0.00457	CbGeAlD
Diclofenac—ABCC4—bone marrow—acquired immunodeficiency syndrome	0.000247	0.00446	CbGeAlD
Diclofenac—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000242	0.00438	CbGeAlD
Diclofenac—ALOX5—brain—acquired immunodeficiency syndrome	0.000232	0.00419	CbGeAlD
Diclofenac—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000224	0.00405	CbGeAlD
Diclofenac—ALOX5—lymph node—acquired immunodeficiency syndrome	0.000224	0.00405	CbGeAlD
Diclofenac—ABCC4—lung—acquired immunodeficiency syndrome	0.000223	0.00404	CbGeAlD
Diclofenac—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000223	0.00402	CbGeAlD
Diclofenac—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000218	0.00394	CbGeAlD
Diclofenac—ABCC1—blood—acquired immunodeficiency syndrome	0.000217	0.00393	CbGeAlD
Diclofenac—CYP2C19—blood—acquired immunodeficiency syndrome	0.000212	0.00383	CbGeAlD
Diclofenac—ABCC4—nervous system—acquired immunodeficiency syndrome	0.000207	0.00374	CbGeAlD
Diclofenac—SLC22A8—nervous system—acquired immunodeficiency syndrome	0.000205	0.00371	CbGeAlD
Diclofenac—ABCC1—vagina—acquired immunodeficiency syndrome	0.000201	0.00364	CbGeAlD
Diclofenac—ABCC4—central nervous system—acquired immunodeficiency syndrome	0.000199	0.0036	CbGeAlD
Diclofenac—SLC22A8—central nervous system—acquired immunodeficiency syndrome	0.000198	0.00357	CbGeAlD
Diclofenac—PTGS1—skin of body—acquired immunodeficiency syndrome	0.000197	0.00356	CbGeAlD
Diclofenac—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000197	0.00355	CbGeAlD
Diclofenac—ABCC1—lung—acquired immunodeficiency syndrome	0.000191	0.00344	CbGeAlD
Diclofenac—PTGS2—skin of body—acquired immunodeficiency syndrome	0.000188	0.0034	CbGeAlD
Diclofenac—CYP2C8—blood—acquired immunodeficiency syndrome	0.000185	0.00334	CbGeAlD
Diclofenac—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000182	0.00328	CbGeAlD
Diclofenac—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000179	0.00324	CbGeAlD
Diclofenac—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000176	0.00319	CbGeAlD
Diclofenac—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.000174	0.00315	CbGeAlD
Diclofenac—CYP1A2—blood—acquired immunodeficiency syndrome	0.000173	0.00313	CbGeAlD
Diclofenac—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000173	0.00312	CbGeAlD
Diclofenac—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000172	0.0031	CbGeAlD
Diclofenac—CYP1A1—blood—acquired immunodeficiency syndrome	0.000171	0.00309	CbGeAlD
Diclofenac—CYP2B6—blood—acquired immunodeficiency syndrome	0.000166	0.003	CbGeAlD
Diclofenac—CYP2E1—lymphoid tissue—acquired immunodeficiency syndrome	0.000166	0.00299	CbGeAlD
Diclofenac—CYP2C9—blood—acquired immunodeficiency syndrome	0.000164	0.00297	CbGeAlD
Diclofenac—CYP2E1—digestive system—acquired immunodeficiency syndrome	0.000164	0.00295	CbGeAlD
Diclofenac—ALB—brain—acquired immunodeficiency syndrome	0.000163	0.00295	CbGeAlD
Diclofenac—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000158	0.00286	CbGeAlD
Diclofenac—ABCC4—brain—acquired immunodeficiency syndrome	0.000158	0.00286	CbGeAlD
Diclofenac—ALB—lymph node—acquired immunodeficiency syndrome	0.000158	0.00285	CbGeAlD
Diclofenac—PTGS1—digestive system—acquired immunodeficiency syndrome	0.000158	0.00285	CbGeAlD
Diclofenac—SLC22A8—brain—acquired immunodeficiency syndrome	0.000157	0.00284	CbGeAlD
Diclofenac—CYP2E1—blood—acquired immunodeficiency syndrome	0.000156	0.00282	CbGeAlD
Diclofenac—CYP2B6—vagina—acquired immunodeficiency syndrome	0.000154	0.00278	CbGeAlD
Diclofenac—ABCC4—lymph node—acquired immunodeficiency syndrome	0.000153	0.00276	CbGeAlD
Diclofenac—PTGS2—lymphoid tissue—acquired immunodeficiency syndrome	0.000152	0.00275	CbGeAlD
Diclofenac—CYP1A2—lung—acquired immunodeficiency syndrome	0.000152	0.00274	CbGeAlD
Diclofenac—PTGS2—digestive system—acquired immunodeficiency syndrome	0.000151	0.00272	CbGeAlD
Diclofenac—CYP2E1—spinal cord—acquired immunodeficiency syndrome	0.00015	0.00271	CbGeAlD
Diclofenac—PTGS1—blood—acquired immunodeficiency syndrome	0.00015	0.00271	CbGeAlD
Diclofenac—CYP1A1—lung—acquired immunodeficiency syndrome	0.00015	0.00271	CbGeAlD
Diclofenac—CYP2B6—lung—acquired immunodeficiency syndrome	0.000146	0.00263	CbGeAlD
Diclofenac—PTGS1—spinal cord—acquired immunodeficiency syndrome	0.000145	0.00261	CbGeAlD
Diclofenac—PTGS2—blood—acquired immunodeficiency syndrome	0.000143	0.00259	CbGeAlD
Diclofenac—PTGS1—vagina—acquired immunodeficiency syndrome	0.000139	0.00251	CbGeAlD
Diclofenac—PTGS2—bone marrow—acquired immunodeficiency syndrome	0.000139	0.00251	CbGeAlD
Diclofenac—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000139	0.00251	CbGeAlD
Diclofenac—PTGS2—spinal cord—acquired immunodeficiency syndrome	0.000138	0.0025	CbGeAlD
Diclofenac—CYP2E1—lung—acquired immunodeficiency syndrome	0.000137	0.00247	CbGeAlD
Diclofenac—ABCC1—brain—acquired immunodeficiency syndrome	0.000135	0.00244	CbGeAlD
Diclofenac—CYP2B6—nervous system—acquired immunodeficiency syndrome	0.000135	0.00244	CbGeAlD
Diclofenac—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.000133	0.00241	CbGeAlD
Diclofenac—PTGS2—vagina—acquired immunodeficiency syndrome	0.000133	0.0024	CbGeAlD
Diclofenac—ABCB1—retina—acquired immunodeficiency syndrome	0.000133	0.0024	CbGeAlD
Diclofenac—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000132	0.00238	CbGeAlD
Diclofenac—PTGS1—lung—acquired immunodeficiency syndrome	0.000132	0.00238	CbGeAlD
Diclofenac—ABCC1—lymph node—acquired immunodeficiency syndrome	0.00013	0.00235	CbGeAlD
Diclofenac—CYP2B6—central nervous system—acquired immunodeficiency syndrome	0.00013	0.00234	CbGeAlD
Diclofenac—CYP2E1—nervous system—acquired immunodeficiency syndrome	0.000126	0.00229	CbGeAlD
Diclofenac—PTGS2—lung—acquired immunodeficiency syndrome	0.000126	0.00227	CbGeAlD
Diclofenac—CYP3A4—blood—acquired immunodeficiency syndrome	0.000125	0.00227	CbGeAlD
Diclofenac—PTGS1—nervous system—acquired immunodeficiency syndrome	0.000122	0.0022	CbGeAlD
Diclofenac—CYP2E1—central nervous system—acquired immunodeficiency syndrome	0.000122	0.0022	CbGeAlD
Diclofenac—PTGS1—central nervous system—acquired immunodeficiency syndrome	0.000117	0.00212	CbGeAlD
Diclofenac—PTGS2—nervous system—acquired immunodeficiency syndrome	0.000116	0.0021	CbGeAlD
Diclofenac—CYP2C8—brain—acquired immunodeficiency syndrome	0.000115	0.00208	CbGeAlD
Diclofenac—PTGS2—central nervous system—acquired immunodeficiency syndrome	0.000112	0.00203	CbGeAlD
Diclofenac—CYP1A1—brain—acquired immunodeficiency syndrome	0.000106	0.00192	CbGeAlD
Diclofenac—CYP2B6—brain—acquired immunodeficiency syndrome	0.000103	0.00186	CbGeAlD
Diclofenac—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000102	0.00185	CbGeAlD
Diclofenac—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000102	0.00184	CbGeAlD
Diclofenac—CYP3A4—central nervous system—acquired immunodeficiency syndrome	9.8e-05	0.00177	CbGeAlD
Diclofenac—CYP2E1—brain—acquired immunodeficiency syndrome	9.67e-05	0.00175	CbGeAlD
Diclofenac—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	9.43e-05	0.0017	CbGeAlD
Diclofenac—ABCB1—digestive system—acquired immunodeficiency syndrome	9.31e-05	0.00168	CbGeAlD
Diclofenac—PTGS1—brain—acquired immunodeficiency syndrome	9.31e-05	0.00168	CbGeAlD
Diclofenac—PTGS1—lymph node—acquired immunodeficiency syndrome	9e-05	0.00163	CbGeAlD
Diclofenac—PTGS2—brain—acquired immunodeficiency syndrome	8.9e-05	0.00161	CbGeAlD
Diclofenac—ABCB1—blood—acquired immunodeficiency syndrome	8.87e-05	0.0016	CbGeAlD
Diclofenac—PTGS2—lymph node—acquired immunodeficiency syndrome	8.6e-05	0.00155	CbGeAlD
Diclofenac—ABCB1—bone marrow—acquired immunodeficiency syndrome	8.58e-05	0.00155	CbGeAlD
Diclofenac—ABCB1—spinal cord—acquired immunodeficiency syndrome	8.55e-05	0.00154	CbGeAlD
Diclofenac—ABCB1—vagina—acquired immunodeficiency syndrome	8.22e-05	0.00149	CbGeAlD
Diclofenac—ABCB1—lung—acquired immunodeficiency syndrome	7.78e-05	0.00141	CbGeAlD
Diclofenac—ABCB1—nervous system—acquired immunodeficiency syndrome	7.2e-05	0.0013	CbGeAlD
Diclofenac—ABCB1—central nervous system—acquired immunodeficiency syndrome	6.93e-05	0.00125	CbGeAlD
Diclofenac—PLA2G2A—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	6.08e-05	0.00124	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.08e-05	0.00124	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—TNF—acquired immunodeficiency syndrome	5.99e-05	0.00122	CbGpPWpGaD
Diclofenac—CXCR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.97e-05	0.00122	CbGpPWpGaD
Diclofenac—CXCR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.97e-05	0.00122	CbGpPWpGaD
Diclofenac—CXCL8—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	5.96e-05	0.00122	CbGpPWpGaD
Diclofenac—CXCL8—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	5.95e-05	0.00122	CbGpPWpGaD
Diclofenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—acquired immunodeficiency syndrome	5.84e-05	0.00119	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism—AGPS—acquired immunodeficiency syndrome	5.77e-05	0.00118	CbGpPWpGaD
Diclofenac—ALOX5—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	5.64e-05	0.00115	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.62e-05	0.00115	CbGpPWpGaD
Diclofenac—CXCL8—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	5.59e-05	0.00114	CbGpPWpGaD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	5.54e-05	0.00113	CbGpPWpGaD
Diclofenac—ABCB1—brain—acquired immunodeficiency syndrome	5.51e-05	0.000995	CbGeAlD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	5.44e-05	0.00031	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	5.42e-05	0.000309	CcSEcCtD
Diclofenac—Pruritus—Abacavir—acquired immunodeficiency syndrome	5.41e-05	0.000309	CcSEcCtD
Diclofenac—Fatigue—Indinavir—acquired immunodeficiency syndrome	5.41e-05	0.000309	CcSEcCtD
Diclofenac—Anorexia—Delavirdine—acquired immunodeficiency syndrome	5.41e-05	0.000308	CcSEcCtD
Diclofenac—Discomfort—Ritonavir—acquired immunodeficiency syndrome	5.41e-05	0.000308	CcSEcCtD
Diclofenac—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	5.4e-05	0.000308	CcSEcCtD
Diclofenac—Cough—Saquinavir—acquired immunodeficiency syndrome	5.4e-05	0.000308	CcSEcCtD
Diclofenac—Angioedema—Lamivudine—acquired immunodeficiency syndrome	5.4e-05	0.000308	CcSEcCtD
Diclofenac—Pain—Indinavir—acquired immunodeficiency syndrome	5.37e-05	0.000306	CcSEcCtD
Diclofenac—Constipation—Indinavir—acquired immunodeficiency syndrome	5.37e-05	0.000306	CcSEcCtD
Diclofenac—Insomnia—Efavirenz—acquired immunodeficiency syndrome	5.37e-05	0.000306	CcSEcCtD
Diclofenac—Urticaria—Zidovudine—acquired immunodeficiency syndrome	5.36e-05	0.000306	CcSEcCtD
Diclofenac—Convulsion—Saquinavir—acquired immunodeficiency syndrome	5.36e-05	0.000306	CcSEcCtD
Diclofenac—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	5.36e-05	0.000305	CcSEcCtD
Diclofenac—ABCC4—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	5.35e-05	0.00109	CbGpPWpGaD
Diclofenac—Hypertension—Saquinavir—acquired immunodeficiency syndrome	5.34e-05	0.000305	CcSEcCtD
Diclofenac—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	5.34e-05	0.000304	CcSEcCtD
Diclofenac—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	5.34e-05	0.000304	CcSEcCtD
Diclofenac—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	5.33e-05	0.000304	CcSEcCtD
Diclofenac—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	5.33e-05	0.000304	CcSEcCtD
Diclofenac—Malaise—Lamivudine—acquired immunodeficiency syndrome	5.33e-05	0.000304	CcSEcCtD
Diclofenac—CXCL8—AP-1 transcription factor network—IL6—acquired immunodeficiency syndrome	5.32e-05	0.00109	CbGpPWpGaD
Diclofenac—ABCB1—lymph node—acquired immunodeficiency syndrome	5.32e-05	0.000961	CbGeAlD
Diclofenac—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	5.31e-05	0.000303	CcSEcCtD
Diclofenac—Nausea—Didanosine—acquired immunodeficiency syndrome	5.31e-05	0.000303	CcSEcCtD
Diclofenac—Vertigo—Lamivudine—acquired immunodeficiency syndrome	5.31e-05	0.000303	CcSEcCtD
Diclofenac—Hypotension—Delavirdine—acquired immunodeficiency syndrome	5.3e-05	0.000302	CcSEcCtD
Diclofenac—Syncope—Lamivudine—acquired immunodeficiency syndrome	5.3e-05	0.000302	CcSEcCtD
Diclofenac—Confusional state—Ritonavir—acquired immunodeficiency syndrome	5.29e-05	0.000302	CcSEcCtD
Diclofenac—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	5.29e-05	0.000302	CcSEcCtD
Diclofenac—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	5.29e-05	0.000301	CcSEcCtD
Diclofenac—Somnolence—Efavirenz—acquired immunodeficiency syndrome	5.27e-05	0.000301	CcSEcCtD
Diclofenac—Chest pain—Saquinavir—acquired immunodeficiency syndrome	5.27e-05	0.0003	CcSEcCtD
Diclofenac—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	5.27e-05	0.0003	CcSEcCtD
Diclofenac—Myalgia—Saquinavir—acquired immunodeficiency syndrome	5.27e-05	0.0003	CcSEcCtD
Diclofenac—CXCL8—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.25e-05	0.00107	CbGpPWpGaD
Diclofenac—CXCL8—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.25e-05	0.00107	CbGpPWpGaD
Diclofenac—Anxiety—Saquinavir—acquired immunodeficiency syndrome	5.25e-05	0.000299	CcSEcCtD
Diclofenac—CXCL8—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.25e-05	0.00107	CbGpPWpGaD
Diclofenac—Oedema—Ritonavir—acquired immunodeficiency syndrome	5.25e-05	0.000299	CcSEcCtD
Diclofenac—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	5.24e-05	0.000299	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	5.23e-05	0.000298	CcSEcCtD
Diclofenac—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	5.22e-05	0.000298	CcSEcCtD
Diclofenac—Discomfort—Saquinavir—acquired immunodeficiency syndrome	5.21e-05	0.000297	CcSEcCtD
Diclofenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—acquired immunodeficiency syndrome	5.19e-05	0.00106	CbGpPWpGaD
Diclofenac—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	5.19e-05	0.000296	CcSEcCtD
Diclofenac—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	5.17e-05	0.000295	CcSEcCtD
Diclofenac—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	5.17e-05	0.000295	CcSEcCtD
Diclofenac—Shock—Ritonavir—acquired immunodeficiency syndrome	5.16e-05	0.000294	CcSEcCtD
Diclofenac—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	5.16e-05	0.000294	CcSEcCtD
Diclofenac—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	5.15e-05	0.000294	CcSEcCtD
Diclofenac—Cough—Lamivudine—acquired immunodeficiency syndrome	5.15e-05	0.000294	CcSEcCtD
Diclofenac—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	5.15e-05	0.000294	CcSEcCtD
Diclofenac—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	5.15e-05	0.000293	CcSEcCtD
Diclofenac—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	5.14e-05	0.000293	CcSEcCtD
Diclofenac—Dizziness—Stavudine—acquired immunodeficiency syndrome	5.14e-05	0.000293	CcSEcCtD
Diclofenac—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	5.13e-05	0.000293	CcSEcCtD
Diclofenac—Insomnia—Delavirdine—acquired immunodeficiency syndrome	5.13e-05	0.000293	CcSEcCtD
Diclofenac—CXCL8—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.13e-05	0.00105	CbGpPWpGaD
Diclofenac—PTGS1—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	5.13e-05	0.00105	CbGpPWpGaD
Diclofenac—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	5.12e-05	0.000292	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	5.12e-05	0.000292	CcSEcCtD
Diclofenac—Convulsion—Lamivudine—acquired immunodeficiency syndrome	5.12e-05	0.000292	CcSEcCtD
Diclofenac—Vomiting—Nevirapine—acquired immunodeficiency syndrome	5.12e-05	0.000292	CcSEcCtD
Diclofenac—Fatigue—Efavirenz—acquired immunodeficiency syndrome	5.11e-05	0.000292	CcSEcCtD
Diclofenac—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	5.1e-05	0.000291	CcSEcCtD
Diclofenac—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	5.1e-05	0.000291	CcSEcCtD
Diclofenac—Confusional state—Saquinavir—acquired immunodeficiency syndrome	5.09e-05	0.00029	CcSEcCtD
Diclofenac—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	5.07e-05	0.000289	CcSEcCtD
Diclofenac—Constipation—Efavirenz—acquired immunodeficiency syndrome	5.07e-05	0.000289	CcSEcCtD
Diclofenac—Pain—Efavirenz—acquired immunodeficiency syndrome	5.07e-05	0.000289	CcSEcCtD
Diclofenac—Rash—Nevirapine—acquired immunodeficiency syndrome	5.07e-05	0.000289	CcSEcCtD
Diclofenac—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	5.07e-05	0.000289	CcSEcCtD
Diclofenac—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	5.06e-05	0.000289	CcSEcCtD
Diclofenac—Dizziness—Abacavir—acquired immunodeficiency syndrome	5.06e-05	0.000289	CcSEcCtD
Diclofenac—Oedema—Saquinavir—acquired immunodeficiency syndrome	5.05e-05	0.000288	CcSEcCtD
Diclofenac—Somnolence—Delavirdine—acquired immunodeficiency syndrome	5.05e-05	0.000288	CcSEcCtD
Diclofenac—Headache—Nevirapine—acquired immunodeficiency syndrome	5.04e-05	0.000287	CcSEcCtD
Diclofenac—Chest pain—Lamivudine—acquired immunodeficiency syndrome	5.03e-05	0.000287	CcSEcCtD
Diclofenac—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	5.03e-05	0.000287	CcSEcCtD
Diclofenac—Myalgia—Lamivudine—acquired immunodeficiency syndrome	5.03e-05	0.000287	CcSEcCtD
Diclofenac—Infection—Saquinavir—acquired immunodeficiency syndrome	5.02e-05	0.000286	CcSEcCtD
Diclofenac—Anxiety—Lamivudine—acquired immunodeficiency syndrome	5.01e-05	0.000286	CcSEcCtD
Diclofenac—CXCR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.01e-05	0.00102	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.01e-05	0.00102	CbGpPWpGaD
Diclofenac—Anorexia—Ritonavir—acquired immunodeficiency syndrome	5e-05	0.000285	CcSEcCtD
Diclofenac—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	5e-05	0.000285	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	4.99e-05	0.000285	CcSEcCtD
Diclofenac—Urticaria—Indinavir—acquired immunodeficiency syndrome	4.99e-05	0.000284	CcSEcCtD
Diclofenac—Shock—Saquinavir—acquired immunodeficiency syndrome	4.97e-05	0.000283	CcSEcCtD
Diclofenac—Discomfort—Lamivudine—acquired immunodeficiency syndrome	4.97e-05	0.000283	CcSEcCtD
Diclofenac—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	4.96e-05	0.000283	CcSEcCtD
Diclofenac—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	4.96e-05	0.000283	CcSEcCtD
Diclofenac—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	4.95e-05	0.000282	CcSEcCtD
Diclofenac—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	4.95e-05	0.000282	CcSEcCtD
Diclofenac—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	4.95e-05	0.000282	CcSEcCtD
Diclofenac—Vomiting—Stavudine—acquired immunodeficiency syndrome	4.94e-05	0.000282	CcSEcCtD
Diclofenac—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	4.93e-05	0.000281	CcSEcCtD
Diclofenac—CXCR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.93e-05	0.00101	CbGpPWpGaD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	4.93e-05	0.00101	CbGpPWpGaD
Diclofenac—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	4.92e-05	0.00028	CcSEcCtD
Diclofenac—Rash—Nelfinavir—acquired immunodeficiency syndrome	4.91e-05	0.00028	CcSEcCtD
Diclofenac—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	4.91e-05	0.00028	CcSEcCtD
Diclofenac—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	4.91e-05	0.00028	CcSEcCtD
Diclofenac—Hypotension—Ritonavir—acquired immunodeficiency syndrome	4.9e-05	0.00028	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	4.9e-05	0.000279	CcSEcCtD
Diclofenac—Rash—Stavudine—acquired immunodeficiency syndrome	4.9e-05	0.000279	CcSEcCtD
Diclofenac—Fatigue—Delavirdine—acquired immunodeficiency syndrome	4.89e-05	0.000279	CcSEcCtD
Diclofenac—Dermatitis—Stavudine—acquired immunodeficiency syndrome	4.89e-05	0.000279	CcSEcCtD
Diclofenac—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	4.89e-05	0.000279	CcSEcCtD
Diclofenac—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	4.89e-05	0.000999	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	4.89e-05	0.000999	CbGpPWpGaD
Diclofenac—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	4.88e-05	0.000278	CcSEcCtD
Diclofenac—Headache—Nelfinavir—acquired immunodeficiency syndrome	4.88e-05	0.000278	CcSEcCtD
Diclofenac—CXCL8—Toll-like Receptor Signaling Pathway—TNF—acquired immunodeficiency syndrome	4.88e-05	0.000998	CbGpPWpGaD
Diclofenac—Headache—Stavudine—acquired immunodeficiency syndrome	4.87e-05	0.000277	CcSEcCtD
Diclofenac—Vomiting—Abacavir—acquired immunodeficiency syndrome	4.87e-05	0.000277	CcSEcCtD
Diclofenac—PTGS2—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	4.86e-05	0.000995	CbGpPWpGaD
Diclofenac—Confusional state—Lamivudine—acquired immunodeficiency syndrome	4.86e-05	0.000277	CcSEcCtD
Diclofenac—Constipation—Delavirdine—acquired immunodeficiency syndrome	4.85e-05	0.000277	CcSEcCtD
Diclofenac—Pain—Delavirdine—acquired immunodeficiency syndrome	4.85e-05	0.000277	CcSEcCtD
Diclofenac—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	4.85e-05	0.000277	CcSEcCtD
Diclofenac—Asthenia—Zidovudine—acquired immunodeficiency syndrome	4.84e-05	0.000276	CcSEcCtD
Diclofenac—Rash—Abacavir—acquired immunodeficiency syndrome	4.82e-05	0.000275	CcSEcCtD
Diclofenac—Dermatitis—Abacavir—acquired immunodeficiency syndrome	4.82e-05	0.000275	CcSEcCtD
Diclofenac—Oedema—Lamivudine—acquired immunodeficiency syndrome	4.82e-05	0.000275	CcSEcCtD
Diclofenac—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	4.82e-05	0.000275	CcSEcCtD
Diclofenac—Anorexia—Saquinavir—acquired immunodeficiency syndrome	4.82e-05	0.000275	CcSEcCtD
Diclofenac—Headache—Abacavir—acquired immunodeficiency syndrome	4.79e-05	0.000273	CcSEcCtD
Diclofenac—Infection—Lamivudine—acquired immunodeficiency syndrome	4.79e-05	0.000273	CcSEcCtD
Diclofenac—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	4.78e-05	0.000273	CcSEcCtD
Diclofenac—Nausea—Nevirapine—acquired immunodeficiency syndrome	4.78e-05	0.000272	CcSEcCtD
Diclofenac—Pruritus—Zidovudine—acquired immunodeficiency syndrome	4.78e-05	0.000272	CcSEcCtD
Diclofenac—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	4.75e-05	0.000972	CbGpPWpGaD
Diclofenac—Insomnia—Ritonavir—acquired immunodeficiency syndrome	4.75e-05	0.000271	CcSEcCtD
Diclofenac—Shock—Lamivudine—acquired immunodeficiency syndrome	4.74e-05	0.00027	CcSEcCtD
Diclofenac—CXCL8—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.73e-05	0.000967	CbGpPWpGaD
Diclofenac—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	4.73e-05	0.000269	CcSEcCtD
Diclofenac—Hypotension—Saquinavir—acquired immunodeficiency syndrome	4.72e-05	0.000269	CcSEcCtD
Diclofenac—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	4.72e-05	0.000269	CcSEcCtD
Diclofenac—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	4.71e-05	0.000269	CcSEcCtD
Diclofenac—Urticaria—Efavirenz—acquired immunodeficiency syndrome	4.71e-05	0.000269	CcSEcCtD
Diclofenac—CXCL8—Glucocorticoid receptor regulatory network—IL6—acquired immunodeficiency syndrome	4.69e-05	0.000959	CbGpPWpGaD
Diclofenac—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	4.69e-05	0.000267	CcSEcCtD
Diclofenac—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	4.69e-05	0.000267	CcSEcCtD
Diclofenac—PTGS1—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	4.68e-05	0.000958	CbGpPWpGaD
Diclofenac—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	4.68e-05	0.000267	CcSEcCtD
Diclofenac—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	4.68e-05	0.000267	CcSEcCtD
Diclofenac—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	4.68e-05	0.000267	CcSEcCtD
Diclofenac—Somnolence—Ritonavir—acquired immunodeficiency syndrome	4.67e-05	0.000266	CcSEcCtD
Diclofenac—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	4.66e-05	0.000266	CcSEcCtD
Diclofenac—ALB—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	4.65e-05	0.000952	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	4.65e-05	0.00095	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.64e-05	0.000949	CbGpPWpGaD
Diclofenac—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	4.64e-05	0.000265	CcSEcCtD
Diclofenac—Nausea—Nelfinavir—acquired immunodeficiency syndrome	4.63e-05	0.000264	CcSEcCtD
Diclofenac—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	4.63e-05	0.000264	CcSEcCtD
Diclofenac—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	4.62e-05	0.000263	CcSEcCtD
Diclofenac—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	4.62e-05	0.000263	CcSEcCtD
Diclofenac—Nausea—Stavudine—acquired immunodeficiency syndrome	4.61e-05	0.000263	CcSEcCtD
Diclofenac—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	4.6e-05	0.000262	CcSEcCtD
Diclofenac—Anorexia—Lamivudine—acquired immunodeficiency syndrome	4.59e-05	0.000262	CcSEcCtD
Diclofenac—Insomnia—Saquinavir—acquired immunodeficiency syndrome	4.57e-05	0.000261	CcSEcCtD
Diclofenac—CYP2C18—Metabolism—TAT—acquired immunodeficiency syndrome	4.57e-05	0.000934	CbGpPWpGaD
Diclofenac—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	4.56e-05	0.00026	CcSEcCtD
Diclofenac—CXCR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.55e-05	0.00093	CbGpPWpGaD
Diclofenac—Nausea—Abacavir—acquired immunodeficiency syndrome	4.55e-05	0.000259	CcSEcCtD
Diclofenac—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	4.54e-05	0.000259	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	4.53e-05	0.000258	CcSEcCtD
Diclofenac—Fatigue—Ritonavir—acquired immunodeficiency syndrome	4.53e-05	0.000258	CcSEcCtD
Diclofenac—TTR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.52e-05	0.000925	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.52e-05	0.000925	CbGpPWpGaD
Diclofenac—CXCR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.51e-05	0.000922	CbGpPWpGaD
Diclofenac—Urticaria—Delavirdine—acquired immunodeficiency syndrome	4.51e-05	0.000257	CcSEcCtD
Diclofenac—Asthenia—Indinavir—acquired immunodeficiency syndrome	4.51e-05	0.000257	CcSEcCtD
Diclofenac—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	4.5e-05	0.000257	CcSEcCtD
Diclofenac—Hypotension—Lamivudine—acquired immunodeficiency syndrome	4.5e-05	0.000257	CcSEcCtD
Diclofenac—Somnolence—Saquinavir—acquired immunodeficiency syndrome	4.49e-05	0.000256	CcSEcCtD
Diclofenac—Pain—Ritonavir—acquired immunodeficiency syndrome	4.49e-05	0.000256	CcSEcCtD
Diclofenac—Constipation—Ritonavir—acquired immunodeficiency syndrome	4.49e-05	0.000256	CcSEcCtD
Diclofenac—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	4.49e-05	0.000256	CcSEcCtD
Diclofenac—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	4.49e-05	0.000256	CcSEcCtD
Diclofenac—CXCR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.48e-05	0.000916	CbGpPWpGaD
Diclofenac—Dizziness—Zidovudine—acquired immunodeficiency syndrome	4.46e-05	0.000255	CcSEcCtD
Diclofenac—PTGS2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.46e-05	0.000913	CbGpPWpGaD
Diclofenac—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	4.45e-05	0.000254	CcSEcCtD
Diclofenac—UGT2B7—Metabolism—TAT—acquired immunodeficiency syndrome	4.44e-05	0.000909	CbGpPWpGaD
Diclofenac—Pruritus—Indinavir—acquired immunodeficiency syndrome	4.44e-05	0.000253	CcSEcCtD
Diclofenac—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	4.39e-05	0.00025	CcSEcCtD
Diclofenac—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	4.39e-05	0.00025	CcSEcCtD
Diclofenac—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	4.37e-05	0.000249	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	4.36e-05	0.000249	CcSEcCtD
Diclofenac—Insomnia—Lamivudine—acquired immunodeficiency syndrome	4.36e-05	0.000249	CcSEcCtD
Diclofenac—Fatigue—Saquinavir—acquired immunodeficiency syndrome	4.36e-05	0.000248	CcSEcCtD
Diclofenac—CXCL8—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	4.34e-05	0.000888	CbGpPWpGaD
Diclofenac—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	4.33e-05	0.000247	CcSEcCtD
Diclofenac—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	4.33e-05	0.000247	CcSEcCtD
Diclofenac—Pain—Saquinavir—acquired immunodeficiency syndrome	4.32e-05	0.000246	CcSEcCtD
Diclofenac—Constipation—Saquinavir—acquired immunodeficiency syndrome	4.32e-05	0.000246	CcSEcCtD
Diclofenac—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	4.3e-05	0.000245	CcSEcCtD
Diclofenac—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	4.3e-05	0.000245	CcSEcCtD
Diclofenac—Vomiting—Zidovudine—acquired immunodeficiency syndrome	4.29e-05	0.000245	CcSEcCtD
Diclofenac—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	4.29e-05	0.000245	CcSEcCtD
Diclofenac—Somnolence—Lamivudine—acquired immunodeficiency syndrome	4.28e-05	0.000244	CcSEcCtD
Diclofenac—Rash—Zidovudine—acquired immunodeficiency syndrome	4.26e-05	0.000243	CcSEcCtD
Diclofenac—Asthenia—Efavirenz—acquired immunodeficiency syndrome	4.26e-05	0.000243	CcSEcCtD
Diclofenac—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	4.25e-05	0.000242	CcSEcCtD
Diclofenac—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	4.24e-05	0.000242	CcSEcCtD
Diclofenac—Headache—Zidovudine—acquired immunodeficiency syndrome	4.23e-05	0.000241	CcSEcCtD
Diclofenac—Pruritus—Efavirenz—acquired immunodeficiency syndrome	4.2e-05	0.000239	CcSEcCtD
Diclofenac—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	4.19e-05	0.000239	CcSEcCtD
Diclofenac—SLC22A11—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	4.19e-05	0.000856	CbGpPWpGaD
Diclofenac—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	4.18e-05	0.000238	CcSEcCtD
Diclofenac—Urticaria—Ritonavir—acquired immunodeficiency syndrome	4.17e-05	0.000238	CcSEcCtD
Diclofenac—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	4.16e-05	0.000237	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	4.16e-05	0.000237	CcSEcCtD
Diclofenac—Fatigue—Lamivudine—acquired immunodeficiency syndrome	4.16e-05	0.000237	CcSEcCtD
Diclofenac—Dizziness—Indinavir—acquired immunodeficiency syndrome	4.15e-05	0.000237	CcSEcCtD
Diclofenac—CXCR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.15e-05	0.000849	CbGpPWpGaD
Diclofenac—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	4.15e-05	0.000237	CcSEcCtD
Diclofenac—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	4.15e-05	0.000237	CcSEcCtD
Diclofenac—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	4.13e-05	0.000236	CcSEcCtD
Diclofenac—Constipation—Lamivudine—acquired immunodeficiency syndrome	4.12e-05	0.000235	CcSEcCtD
Diclofenac—Pain—Lamivudine—acquired immunodeficiency syndrome	4.12e-05	0.000235	CcSEcCtD
Diclofenac—CXCR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.1e-05	0.000837	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.09e-05	0.000836	CbGpPWpGaD
Diclofenac—PTGS2—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	4.07e-05	0.000833	CbGpPWpGaD
Diclofenac—Asthenia—Delavirdine—acquired immunodeficiency syndrome	4.07e-05	0.000232	CcSEcCtD
Diclofenac—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	4.06e-05	0.000231	CcSEcCtD
Diclofenac—PTGS2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	4.04e-05	0.000827	CbGpPWpGaD
Diclofenac—Pruritus—Delavirdine—acquired immunodeficiency syndrome	4.02e-05	0.000229	CcSEcCtD
Diclofenac—Urticaria—Saquinavir—acquired immunodeficiency syndrome	4.01e-05	0.000229	CcSEcCtD
Diclofenac—Nausea—Zidovudine—acquired immunodeficiency syndrome	4.01e-05	0.000229	CcSEcCtD
Diclofenac—CXCL8—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4e-05	0.000818	CbGpPWpGaD
Diclofenac—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	3.99e-05	0.000228	CcSEcCtD
Diclofenac—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	3.99e-05	0.000228	CcSEcCtD
Diclofenac—Vomiting—Indinavir—acquired immunodeficiency syndrome	3.99e-05	0.000228	CcSEcCtD
Diclofenac—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	3.97e-05	0.000226	CcSEcCtD
Diclofenac—CYP1A1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.96e-05	0.00081	CbGpPWpGaD
Diclofenac—Rash—Indinavir—acquired immunodeficiency syndrome	3.96e-05	0.000226	CcSEcCtD
Diclofenac—Dermatitis—Indinavir—acquired immunodeficiency syndrome	3.96e-05	0.000226	CcSEcCtD
Diclofenac—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	3.94e-05	0.000225	CcSEcCtD
Diclofenac—CXCL8—Toll-like Receptor Signaling Pathway—IL6—acquired immunodeficiency syndrome	3.94e-05	0.000805	CbGpPWpGaD
Diclofenac—Headache—Indinavir—acquired immunodeficiency syndrome	3.93e-05	0.000224	CcSEcCtD
Diclofenac—Dizziness—Efavirenz—acquired immunodeficiency syndrome	3.92e-05	0.000224	CcSEcCtD
Diclofenac—CYP2C18—Metabolism—AGPS—acquired immunodeficiency syndrome	3.88e-05	0.000794	CbGpPWpGaD
Diclofenac—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	3.88e-05	0.000221	CcSEcCtD
Diclofenac—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	3.87e-05	0.00022	CcSEcCtD
Diclofenac—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—IL6—acquired immunodeficiency syndrome	3.85e-05	0.000787	CbGpPWpGaD
Diclofenac—CXCL8—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	3.85e-05	0.000787	CbGpPWpGaD
Diclofenac—Urticaria—Lamivudine—acquired immunodeficiency syndrome	3.83e-05	0.000218	CcSEcCtD
Diclofenac—CXCL8—Regulation of toll-like receptor signaling pathway—TNF—acquired immunodeficiency syndrome	3.81e-05	0.000779	CbGpPWpGaD
Diclofenac—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	3.81e-05	0.000217	CcSEcCtD
Diclofenac—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	3.81e-05	0.000217	CcSEcCtD
Diclofenac—ALB—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	3.79e-05	0.000774	CbGpPWpGaD
Diclofenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—acquired immunodeficiency syndrome	3.78e-05	0.000773	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—AGPS—acquired immunodeficiency syndrome	3.78e-05	0.000773	CbGpPWpGaD
Diclofenac—Vomiting—Efavirenz—acquired immunodeficiency syndrome	3.77e-05	0.000215	CcSEcCtD
Diclofenac—Asthenia—Ritonavir—acquired immunodeficiency syndrome	3.77e-05	0.000215	CcSEcCtD
Diclofenac—CXCR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.75e-05	0.000768	CbGpPWpGaD
Diclofenac—Dizziness—Delavirdine—acquired immunodeficiency syndrome	3.75e-05	0.000214	CcSEcCtD
Diclofenac—Rash—Efavirenz—acquired immunodeficiency syndrome	3.74e-05	0.000213	CcSEcCtD
Diclofenac—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	3.74e-05	0.000213	CcSEcCtD
Diclofenac—Nausea—Indinavir—acquired immunodeficiency syndrome	3.73e-05	0.000213	CcSEcCtD
Diclofenac—PTGS2—C-MYB transcription factor network—CD4—acquired immunodeficiency syndrome	3.73e-05	0.000762	CbGpPWpGaD
Diclofenac—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	3.72e-05	0.000212	CcSEcCtD
Diclofenac—PTGS2—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	3.72e-05	0.00076	CbGpPWpGaD
Diclofenac—Headache—Efavirenz—acquired immunodeficiency syndrome	3.72e-05	0.000212	CcSEcCtD
Diclofenac—Pruritus—Ritonavir—acquired immunodeficiency syndrome	3.71e-05	0.000212	CcSEcCtD
Diclofenac—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.63e-05	0.000743	CbGpPWpGaD
Diclofenac—Asthenia—Saquinavir—acquired immunodeficiency syndrome	3.62e-05	0.000207	CcSEcCtD
Diclofenac—PLA2G2A—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.62e-05	0.000741	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—TAT—acquired immunodeficiency syndrome	3.61e-05	0.000739	CbGpPWpGaD
Diclofenac—ALB—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.61e-05	0.000738	CbGpPWpGaD
Diclofenac—Vomiting—Delavirdine—acquired immunodeficiency syndrome	3.61e-05	0.000206	CcSEcCtD
Diclofenac—CXCL8—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.6e-05	0.000737	CbGpPWpGaD
Diclofenac—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	3.59e-05	0.000205	CcSEcCtD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	3.59e-05	0.000734	CbGpPWpGaD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	3.59e-05	0.000734	CbGpPWpGaD
Diclofenac—Rash—Delavirdine—acquired immunodeficiency syndrome	3.58e-05	0.000204	CcSEcCtD
Diclofenac—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	3.58e-05	0.000204	CcSEcCtD
Diclofenac—Pruritus—Saquinavir—acquired immunodeficiency syndrome	3.57e-05	0.000204	CcSEcCtD
Diclofenac—Headache—Delavirdine—acquired immunodeficiency syndrome	3.56e-05	0.000203	CcSEcCtD
Diclofenac—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	3.55e-05	0.000202	CcSEcCtD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	3.53e-05	0.000723	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.53e-05	0.000722	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.53e-05	0.000722	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—IFNA1—acquired immunodeficiency syndrome	3.52e-05	0.000721	CbGpPWpGaD
Diclofenac—Nausea—Efavirenz—acquired immunodeficiency syndrome	3.52e-05	0.000201	CcSEcCtD
Diclofenac—CXCL8—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	3.51e-05	0.000717	CbGpPWpGaD
Diclofenac—ABCC4—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	3.49e-05	0.000713	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—TAT—acquired immunodeficiency syndrome	3.48e-05	0.000712	CbGpPWpGaD
Diclofenac—CXCL8—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	3.47e-05	0.000711	CbGpPWpGaD
Diclofenac—Dizziness—Ritonavir—acquired immunodeficiency syndrome	3.47e-05	0.000198	CcSEcCtD
Diclofenac—Asthenia—Lamivudine—acquired immunodeficiency syndrome	3.46e-05	0.000197	CcSEcCtD
Diclofenac—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	3.46e-05	0.000197	CcSEcCtD
Diclofenac—Pruritus—Lamivudine—acquired immunodeficiency syndrome	3.41e-05	0.000194	CcSEcCtD
Diclofenac—TTR—Disease—CXCR4—acquired immunodeficiency syndrome	3.39e-05	0.000694	CbGpPWpGaD
Diclofenac—Nausea—Delavirdine—acquired immunodeficiency syndrome	3.37e-05	0.000192	CcSEcCtD
Diclofenac—ALB—Folate Metabolism—IL2—acquired immunodeficiency syndrome	3.36e-05	0.000688	CbGpPWpGaD
Diclofenac—Dizziness—Saquinavir—acquired immunodeficiency syndrome	3.34e-05	0.00019	CcSEcCtD
Diclofenac—Vomiting—Ritonavir—acquired immunodeficiency syndrome	3.34e-05	0.00019	CcSEcCtD
Diclofenac—ABCC1—Disease—APOBEC3G—acquired immunodeficiency syndrome	3.32e-05	0.00068	CbGpPWpGaD
Diclofenac—Rash—Ritonavir—acquired immunodeficiency syndrome	3.31e-05	0.000189	CcSEcCtD
Diclofenac—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	3.31e-05	0.000189	CcSEcCtD
Diclofenac—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	3.3e-05	0.000188	CcSEcCtD
Diclofenac—Headache—Ritonavir—acquired immunodeficiency syndrome	3.29e-05	0.000187	CcSEcCtD
Diclofenac—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.24e-05	0.000663	CbGpPWpGaD
Diclofenac—SLCO1C1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.24e-05	0.000662	CbGpPWpGaD
Diclofenac—Vomiting—Saquinavir—acquired immunodeficiency syndrome	3.21e-05	0.000183	CcSEcCtD
Diclofenac—SLC22A8—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.19e-05	0.000653	CbGpPWpGaD
Diclofenac—Dizziness—Lamivudine—acquired immunodeficiency syndrome	3.19e-05	0.000182	CcSEcCtD
Diclofenac—Rash—Saquinavir—acquired immunodeficiency syndrome	3.19e-05	0.000182	CcSEcCtD
Diclofenac—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	3.18e-05	0.000181	CcSEcCtD
Diclofenac—CXCL8—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.17e-05	0.000649	CbGpPWpGaD
Diclofenac—Headache—Saquinavir—acquired immunodeficiency syndrome	3.17e-05	0.00018	CcSEcCtD
Diclofenac—CXCL8—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.16e-05	0.000646	CbGpPWpGaD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	3.14e-05	0.000642	CbGpPWpGaD
Diclofenac—Nausea—Ritonavir—acquired immunodeficiency syndrome	3.12e-05	0.000178	CcSEcCtD
Diclofenac—CXCL8—Regulation of toll-like receptor signaling pathway—IL6—acquired immunodeficiency syndrome	3.07e-05	0.000629	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	3.07e-05	0.000628	CbGpPWpGaD
Diclofenac—Vomiting—Lamivudine—acquired immunodeficiency syndrome	3.06e-05	0.000175	CcSEcCtD
Diclofenac—Rash—Lamivudine—acquired immunodeficiency syndrome	3.04e-05	0.000173	CcSEcCtD
Diclofenac—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	3.04e-05	0.000173	CcSEcCtD
Diclofenac—CXCL8—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.03e-05	0.00062	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.03e-05	0.00062	CbGpPWpGaD
Diclofenac—PTGS1—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	3.03e-05	0.00062	CbGpPWpGaD
Diclofenac—Headache—Lamivudine—acquired immunodeficiency syndrome	3.02e-05	0.000172	CcSEcCtD
Diclofenac—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	3.01e-05	0.000616	CbGpPWpGaD
Diclofenac—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	3.01e-05	0.000615	CbGpPWpGaD
Diclofenac—Nausea—Saquinavir—acquired immunodeficiency syndrome	3e-05	0.000171	CcSEcCtD
Diclofenac—CXCL8—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.97e-05	0.000607	CbGpPWpGaD
Diclofenac—CXCL8—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.97e-05	0.000607	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.96e-05	0.000606	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.96e-05	0.000604	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—TAT—acquired immunodeficiency syndrome	2.94e-05	0.000602	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	2.94e-05	0.000601	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	2.87e-05	0.000587	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.87e-05	0.000587	CbGpPWpGaD
Diclofenac—Nausea—Lamivudine—acquired immunodeficiency syndrome	2.86e-05	0.000163	CcSEcCtD
Diclofenac—KCNQ2—Axon guidance—IL6—acquired immunodeficiency syndrome	2.86e-05	0.000584	CbGpPWpGaD
Diclofenac—KCNQ3—Axon guidance—IL6—acquired immunodeficiency syndrome	2.86e-05	0.000584	CbGpPWpGaD
Diclofenac—ABCC4—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	2.83e-05	0.000578	CbGpPWpGaD
Diclofenac—ABCC1—Disease—CCNT1—acquired immunodeficiency syndrome	2.83e-05	0.000578	CbGpPWpGaD
Diclofenac—CXCL8—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.8e-05	0.000573	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.79e-05	0.000571	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.76e-05	0.000564	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.74e-05	0.000561	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.7e-05	0.000551	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.7e-05	0.000551	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.69e-05	0.000549	CbGpPWpGaD
Diclofenac—SLC22A6—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	2.67e-05	0.000545	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.66e-05	0.000544	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.64e-05	0.000541	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	2.61e-05	0.000534	CbGpPWpGaD
Diclofenac—CXCR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.61e-05	0.000533	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	2.55e-05	0.000522	CbGpPWpGaD
Diclofenac—KCNQ3—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.53e-05	0.000517	CbGpPWpGaD
Diclofenac—KCNQ2—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.53e-05	0.000517	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.53e-05	0.000517	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.53e-05	0.000516	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.5e-05	0.000512	CbGpPWpGaD
Diclofenac—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	2.45e-05	0.000501	CbGpPWpGaD
Diclofenac—PTGS1—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	2.45e-05	0.0005	CbGpPWpGaD
Diclofenac—CXCL8—Cellular Senescence—IL6—acquired immunodeficiency syndrome	2.44e-05	0.000498	CbGpPWpGaD
Diclofenac—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	2.43e-05	0.000497	CbGpPWpGaD
Diclofenac—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.42e-05	0.000495	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.42e-05	0.000495	CbGpPWpGaD
Diclofenac—PTGS2—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	2.41e-05	0.000492	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.38e-05	0.000486	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.38e-05	0.000486	CbGpPWpGaD
Diclofenac—CXCR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.37e-05	0.000484	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—TAT—acquired immunodeficiency syndrome	2.34e-05	0.000478	CbGpPWpGaD
Diclofenac—TTR—Disease—CCR5—acquired immunodeficiency syndrome	2.32e-05	0.000475	CbGpPWpGaD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	2.29e-05	0.000468	CbGpPWpGaD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	2.29e-05	0.000468	CbGpPWpGaD
Diclofenac—CXCL8—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.26e-05	0.000462	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—TAT—acquired immunodeficiency syndrome	2.25e-05	0.000459	CbGpPWpGaD
Diclofenac—PTGS2—Disease—APOBEC3G—acquired immunodeficiency syndrome	2.23e-05	0.000456	CbGpPWpGaD
Diclofenac—CXCL8—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.23e-05	0.000455	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—TAT—acquired immunodeficiency syndrome	2.2e-05	0.00045	CbGpPWpGaD
Diclofenac—SCN4A—Axon guidance—IL6—acquired immunodeficiency syndrome	2.17e-05	0.000443	CbGpPWpGaD
Diclofenac—SLC22A11—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.13e-05	0.000435	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—TAT—acquired immunodeficiency syndrome	2.07e-05	0.000424	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.05e-05	0.00042	CbGpPWpGaD
Diclofenac—KCNQ3—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.04e-05	0.000417	CbGpPWpGaD
Diclofenac—KCNQ2—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.04e-05	0.000417	CbGpPWpGaD
Diclofenac—CXCL8—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.04e-05	0.000416	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.02e-05	0.000413	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.99e-05	0.000406	CbGpPWpGaD
Diclofenac—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	1.98e-05	0.000404	CbGpPWpGaD
Diclofenac—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	1.95e-05	0.000398	CbGpPWpGaD
Diclofenac—PTGS2—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	1.94e-05	0.000397	CbGpPWpGaD
Diclofenac—SCN4A—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.92e-05	0.000392	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.91e-05	0.000391	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	1.9e-05	0.000389	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	1.9e-05	0.000389	CbGpPWpGaD
Diclofenac—PTGS2—Disease—CCNT1—acquired immunodeficiency syndrome	1.9e-05	0.000388	CbGpPWpGaD
Diclofenac—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	1.89e-05	0.000387	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.87e-05	0.000383	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.87e-05	0.000383	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	1.86e-05	0.00038	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.85e-05	0.000378	CbGpPWpGaD
Diclofenac—CXCL8—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	1.84e-05	0.000376	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.81e-05	0.00037	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—ALB—acquired immunodeficiency syndrome	1.8e-05	0.000368	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.78e-05	0.000364	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.76e-05	0.000361	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	1.7e-05	0.000347	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.69e-05	0.000347	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.66e-05	0.000339	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.63e-05	0.000333	CbGpPWpGaD
Diclofenac—SLC22A8—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.62e-05	0.000332	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	1.62e-05	0.000331	CbGpPWpGaD
Diclofenac—PLA2G2A—Metabolism—ALB—acquired immunodeficiency syndrome	1.61e-05	0.00033	CbGpPWpGaD
Diclofenac—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	1.61e-05	0.000329	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.59e-05	0.000326	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.59e-05	0.000326	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.59e-05	0.000326	CbGpPWpGaD
Diclofenac—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	1.57e-05	0.000321	CbGpPWpGaD
Diclofenac—ABCC4—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.56e-05	0.000318	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	1.55e-05	0.000317	CbGpPWpGaD
Diclofenac—SCN4A—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.55e-05	0.000316	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	1.54e-05	0.000314	CbGpPWpGaD
Diclofenac—ABCC1—Disease—CXCR4—acquired immunodeficiency syndrome	1.48e-05	0.000304	CbGpPWpGaD
Diclofenac—TTR—Disease—CD4—acquired immunodeficiency syndrome	1.46e-05	0.000299	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—IL2—acquired immunodeficiency syndrome	1.46e-05	0.000298	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	1.44e-05	0.000295	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.41e-05	0.000288	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.4e-05	0.000286	CbGpPWpGaD
Diclofenac—CXCR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.39e-05	0.000284	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.36e-05	0.000279	CbGpPWpGaD
Diclofenac—SLC22A6—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.35e-05	0.000277	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.32e-05	0.00027	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.32e-05	0.000269	CbGpPWpGaD
Diclofenac—ABCC1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.3e-05	0.000265	CbGpPWpGaD
Diclofenac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.29e-05	0.000265	CbGpPWpGaD
Diclofenac—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.28e-05	0.000262	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.25e-05	0.000255	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.21e-05	0.000248	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.19e-05	0.000244	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism—ALB—acquired immunodeficiency syndrome	1.18e-05	0.000242	CbGpPWpGaD
Diclofenac—CXCL8—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.18e-05	0.00024	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.15e-05	0.000236	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.12e-05	0.00023	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.09e-05	0.000223	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.07e-05	0.000218	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.02e-05	0.000209	CbGpPWpGaD
Diclofenac—ABCC1—Disease—CCR5—acquired immunodeficiency syndrome	1.02e-05	0.000208	CbGpPWpGaD
Diclofenac—PTGS2—Disease—CXCR4—acquired immunodeficiency syndrome	9.97e-06	0.000204	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.41e-06	0.000192	CbGpPWpGaD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	9.18e-06	0.000188	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	9.15e-06	0.000187	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	8.68e-06	0.000177	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.22e-06	0.000168	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	8.12e-06	0.000166	CbGpPWpGaD
Diclofenac—CYP2C18—Metabolism—ALB—acquired immunodeficiency syndrome	7.97e-06	0.000163	CbGpPWpGaD
Diclofenac—TTR—Disease—IL6—acquired immunodeficiency syndrome	7.89e-06	0.000161	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—ALB—acquired immunodeficiency syndrome	7.75e-06	0.000158	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.45e-06	0.000152	CbGpPWpGaD
Diclofenac—PTGS2—Disease—CCR5—acquired immunodeficiency syndrome	6.83e-06	0.00014	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.65e-06	0.000136	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	6.59e-06	0.000135	CbGpPWpGaD
Diclofenac—ABCC1—Disease—CD4—acquired immunodeficiency syndrome	6.39e-06	0.000131	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.31e-06	0.000129	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—ALB—acquired immunodeficiency syndrome	6.3e-06	0.000129	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.28e-06	0.000128	CbGpPWpGaD
Diclofenac—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	6.17e-06	0.000126	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—ALB—acquired immunodeficiency syndrome	6.07e-06	0.000124	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.06e-06	0.000124	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.53e-06	0.000113	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.18e-06	0.000106	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—ALB—acquired immunodeficiency syndrome	5.13e-06	0.000105	CbGpPWpGaD
Diclofenac—PTGS2—Disease—CD4—acquired immunodeficiency syndrome	4.29e-06	8.77e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—ALB—acquired immunodeficiency syndrome	4.08e-06	8.33e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	3.92e-06	8.01e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—ALB—acquired immunodeficiency syndrome	3.84e-06	7.85e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.71e-06	7.58e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	3.62e-06	7.4e-05	CbGpPWpGaD
Diclofenac—ABCC1—Disease—IL6—acquired immunodeficiency syndrome	3.46e-06	7.07e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	3.32e-06	6.78e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	2.96e-06	6.05e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	2.89e-06	5.91e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	2.7e-06	5.52e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—IL6—acquired immunodeficiency syndrome	2.32e-06	4.74e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	2.31e-06	4.72e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.78e-06	3.64e-05	CbGpPWpGaD
